Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | MAP3K8 |
| Gene Name: | MAP3K8 |
| Protein Full Name: | Mitogen-activated protein kinase kinase kinase 8 |
| Alias: | EC 2.7.11.25; M3K8; MAP3K8; Tpl2; TPL2; TPL-2; Tumor progression locus 2 |
| Mass (Da): | 52925 |
| Number AA: | 467 |
| UniProt ID: | P41279 |
| Locus ID: | 1326 |
| COSMIC ID: | MAP3K8 |
| Gene location on chromosome: | 10p11.23 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20593 |
| Percent of cancer specimens with mutations: | 0.37 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | MAP3K8 is a protein serine/threonine kinase that can activate both MAPK and JNKK pathways. It is required for TLR4 activation of the MEK/ERK pathway. It can activate NF-kB1 by stimulating the proteolysis of its inhibitor, p105, and promote the production of TNF-alpha and IL-2 during T-cell activation. It has been shown to mediate Raf-inhibiting drug resistance in BRAF(V600E) cell lines. MAP3K8 may also play a role in the cell cycle. |